Literature DB >> 14522845

Introduction to the transmissible spongiform encephalopathies or prion diseases.

Bruce Chesebro1.   

Abstract

Sheep scrapie has been known for at least 200 years and was described as a transmissible disease over 100 years ago. Since then, three groups of transmissible spongiform encephalopathies or TSE diseases have been identified in humans including familial, infectious and sporadic types. The discovery of the prion protein (PrP) in the 1980s greatly accelerated knowledge of the biology and pathogenesis of TSE diseases as this protein was found to play a critical role in disease susceptibility and the TSE species-barrier and may also be a component of the infectious agent itself. Nevertheless, the nature of the TSE agents remains an enigma. Proof of the protein-only hypothesis may require generation of biologically active transmissible agent in a cell-free environment where a virus cannot replicate. Conversely, proof of a viral aetiology will require identification and isolation of a candidate virus. Further understanding of the structure of the disease-associated protease-resistant PrP should help elucidate the mechanism of PrP conversion from the normal to the abnormal form. Such information should open up new approaches to both diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522845     DOI: 10.1093/bmb/66.1.1

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  61 in total

1.  Stress granule assembly is mediated by prion-like aggregation of TIA-1.

Authors:  Natalie Gilks; Nancy Kedersha; Maranatha Ayodele; Lily Shen; Georg Stoecklin; Laura M Dember; Paul Anderson
Journal:  Mol Biol Cell       Date:  2004-09-15       Impact factor: 4.138

2.  Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions.

Authors:  Mikael Klingeborn; Brent Race; Kimberly D Meade-White; Bruce Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  Absence of Spiroplasma or other bacterial 16s rRNA genes in brain tissue of hamsters with scrapie.

Authors:  Irina Alexeeva; Ellen J Elliott; Sandra Rollins; Gail E Gasparich; Jozef Lazar; Robert G Rohwer
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 4.  MicroRNAs in neurodegenerative diseases and their therapeutic potential.

Authors:  Eunsung Junn; M Maral Mouradian
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

Review 5.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation.

Authors:  Roger A Moore; Christian Herzog; John Errett; David A Kocisko; Kevin M Arnold; Stanley F Hayes; Suzette A Priola
Journal:  Protein Sci       Date:  2006-02-01       Impact factor: 6.725

7.  Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP.

Authors:  Angelika S Rambold; Margit Miesbauer; Doron Rapaport; Till Bartke; Michael Baier; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  Mol Biol Cell       Date:  2006-05-17       Impact factor: 4.138

Review 8.  Prions of fungi: inherited structures and biological roles.

Authors:  Reed B Wickner; Herman K Edskes; Frank Shewmaker; Toru Nakayashiki
Journal:  Nat Rev Microbiol       Date:  2007-08       Impact factor: 60.633

9.  Stress-protective signalling of prion protein is corrupted by scrapie prions.

Authors:  Angelika S Rambold; Veronika Müller; Uri Ron; Nir Ben-Tal; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

Review 10.  Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Authors:  Erik C Gunther; Stephen M Strittmatter
Journal:  J Mol Med (Berl)       Date:  2009-12-04       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.